Table 2. Clinical significance of IRF3... | Rockefeller University Press

Table 2.

Clinical significance of IRF3 expression in GC

Groups	IRF3 expression				n	Positive	P-value (Fisher’s test)
Groups	–	+	+ +	+ + +	n	Positive	P-value (Fisher’s test)
						%
Gender							0.5761
Male	8	23	25	9	65	87.7
Female	2	6	9	6	23	91.3
Age							0.5336
<60	4	8	10	7	29	86.2
≥60	6	21	24	8	59	89.8
Tumor size							0.0478^{^a}
pT1 + pT2	4	2	3	3	12	66.7
pT3 + pT4	6	27	31	12	76	92.1
Lymph node metastasis							0.0711
N0 + N1	7	14	9	6	36	80.6
N2 + N3	3	15	25	9	52	94.2
Distant metastasis							0.5013
M0	10	29	32	14	85	88.2
M1	0	0	2	1	3	100.0
Tumor stage							0.1097
I + II	6	15	9	7	37	83.8
III + IV	4	14	25	8	51	92.1
Total	10	29	34	15	88

Groups	IRF3 expression				n	Positive	P-value (Fisher’s test)
Groups	–	+	+ +	+ + +	n	Positive	P-value (Fisher’s test)
						%
Gender							0.5761
Male	8	23	25	9	65	87.7
Female	2	6	9	6	23	91.3
Age							0.5336
<60	4	8	10	7	29	86.2
≥60	6	21	24	8	59	89.8
Tumor size							0.0478^{^a}
pT1 + pT2	4	2	3	3	12	66.7
pT3 + pT4	6	27	31	12	76	92.1
Lymph node metastasis							0.0711
N0 + N1	7	14	9	6	36	80.6
N2 + N3	3	15	25	9	52	94.2
Distant metastasis							0.5013
M0	10	29	32	14	85	88.2
M1	0	0	2	1	3	100.0
Tumor stage							0.1097
I + II	6	15	9	7	37	83.8
III + IV	4	14	25	8	51	92.1
Total	10	29	34	15	88

Statistically significant; P < 0.05.